TICKERNERD
Menu
VNDAVNDAHealthcare · Biotechnology

VNDA Stock Forecast: Vanda Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.53
−0.66% on the day

The 5 Wall Street analysts covering Vanda Pharmaceuticals, Inc. hold a median 12-month price target of $11 — +142.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$273.9M
Ticker Nerd rank
47 / 100
Median analyst target
$11
Analysts covering
5
Revenue$50.5M−3.9% y/y
Operating income−$63.8M
Net income−$62.5M
Free cash flow−$31.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
−15.0%
YTD
−48.6%
1Y
−17.0%
From 52W high
−52.6%
From 52W low
+4.9%
$4.32
$9.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VNDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vanda Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Volatility
89
Size
63
Quality
62
Value
49
Momentum
45
Issuance
31
Growth
31
Revisions
26

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (26): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VNDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26VNDAHigh $20Median $11Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $6Median $11High $20

The green dot is the last close — the median target sits +142.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$20
23 Sept 2026OppenheimerInitiatesOutperform—
23 Sept 2026OppenheimerInitiatesOutperform$10
10 Aug 2026B. Riley SecuritiesReiteratesBuy—
10 Aug 2026B. Riley SecuritiesReiteratesBuy$17 → $12
10 Aug 2026HC Wainwright & Co.MaintainsBuy$21 → $20
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy$24 → $21
11 May 2026HC Wainwright & Co.MaintainsBuy—
5 Mar 2026Truist SecuritiesInitiatesBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026HC Wainwright & Co.MaintainsBuy—
31 Dec 2025B. Riley SecuritiesMaintainsBuy—
31 Dec 2025JefferiesMaintainsHold—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025B. Riley SecuritiesInitiatesBuy—
30 Oct 2025Cantor FitzgeraldMaintainsOverweight—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025Cantor FitzgeraldAssumesOverweight$13
7 May 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VNDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VNDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Vanda Pharmaceuticals, Inc. returned −17.0% against +16.2% for the S&P 500, dividends included.

VNDA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26VNDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VNDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Vanda Pharmaceuticals, Inc. (VNDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
126.0×

Cheaper than 6% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−3.9%

Higher than 21% of US stocks

Earnings growth (YoY)
−3.9%

Higher than 32% of US stocks

Gross margin
93.0%

Higher than 97% of US stocks

Operating margin
−126.3%

Higher than 13% of US stocks

Net margin
−127.4%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−77.8%

Higher than 16% of US stocks

Return on assets
−22.4%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vanda Pharmaceuticals, Inc. (VNDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vanda Pharmaceuticals, Inc. has a market value of $273.9M and an enterprise value of $126.7M.

  • Revenue in the twelve months to 30 June 2026: $215.7M. The latest quarter shrank 3.9% year on year.

  • Net income over the same four quarters: −$274.9M, a −127.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.63.

  • Free cash flow in the twelve months to 30 June 2026: −$153.0M.

  • Shares outstanding: 60.5M.

  • Trailing P/E: 126.0×; forward P/E: 22.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vanda Pharmaceuticals, Inc. employs 533 people — $405K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

VNDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VNDAVanda Pharmaceuticals, Inc.$273.9M
47
IKTInhibikase Therapeutics, Inc.$266.5M
40
SABSSAB Biotherapeutics, Inc.$263.0M
39
IPSCCentury Therapeutics, Inc.$262.3M
38
BBOTBridgebio Oncology Therapeutics, Inc.$274.2M
7
VOGXVogenx, Inc.$259.8M
2
ACIUAC Immune SA$259.5M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vanda Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VNDA news & analysis

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

PRNewsWire · 2 Oct 2026neutral

Vanda Pharmaceuticals announced that it will present three posters on imsidolimab for generalized pustular psoriasis (GPP) at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, held from September 30 to October 3, 2026. The presentations cover neutrophil reduction, immunogenicity, and pustulation improvement from the GEMINI-1 study.

Why it matters — The presentations spotlight data on imsidolimab, a key investigational product in Vanda's pipeline for the rare orphan indication GPP, providing visibility into its development progress.

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

PRNewsWire · 29 Sept 2026positive

Vanda Pharmaceuticals announced positive topline results from its pivotal Phase III study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder. The study met its primary endpoint, with the timing of sleep onset shifting 37.1 minutes earlier versus placebo (p=0.022), and 60% of treated participants shifting sleep at least 30 minutes earlier compared to 15% in the placebo arm.

Why it matters — A positive pivotal Phase III result supporting HETLIOZ in a new indication could be significant for Vanda's pipeline and product expansion prospects.

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

PRNewsWire · 2 Sept 2026neutral

Vanda Pharmaceuticals announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026. The announcement was made via press release on September 2, 2026.

Why it matters — Participation at investor conferences gives Vanda management a platform to present company updates and engage with investors and analysts.

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

PRNewsWire · 24 Aug 2026positive

Vanda Pharmaceuticals announced that the European Commission granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), based on a positive opinion from the EMA's Committee for Orphan Medicinal Products. This is the first orphan designation granted by the European Commission for a GPP treatment in the EU, complementing previous US FDA and Japanese designations.

Why it matters — This extends regulatory recognition of imsidolimab to a third major region, strengthening the drug's development position for a severe, potentially life-threatening skin disease.

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

PRNewsWire · 22 Aug 2026positive

Vanda Pharmaceuticals announced that the NEREUS-branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, will race this weekend in the inaugural Freedom 250 Grand Prix in Washington, D.C.

Why it matters — The announcement highlights Vanda's continued sponsorship of the NEREUS brand through the IndyCar racing program, raising brand visibility for the company.

FAQ

Frequently asked questions about VNDA stock

What is the VNDA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Vanda Pharmaceuticals, Inc. have a median 12-month price target of $11, with estimates ranging from $5.75 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNDA stock a buy right now?

Of the 5 analysts covering Vanda Pharmaceuticals, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vanda Pharmaceuticals, Inc. 47 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNDA?

As at 8 Oct 2026, Vanda Pharmaceuticals, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will VNDA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +142.8% from the last close, and Ticker Nerd's factor model ranks Vanda Pharmaceuticals, Inc. 47 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNDA stock forecast for 2030?

No analyst covering Vanda Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.75 to $20 over the next 12 months.

How has VNDA stock performed over the past year?

Vanda Pharmaceuticals, Inc. returned -17.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vanda Pharmaceuticals, Inc. do?

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs.

What is the latest news on VNDA?

The most recent item we track (PRNewsWire, 2 Oct 2026): "Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting". Vanda Pharmaceuticals announced that it will present three posters on imsidolimab for generalized pustular psoriasis (GPP) at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, held from September 30 to October 3, 2026. The presentations cover neutrophil reduction, immunogenicity, and pustulation improvement from the GEMINI-1 study.

Company

About Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.

CEO Dr. Mihael H. Polymeropoulos M.D. · 533 employees · United States · https://www.vandapharma.com